颅内出血患者合并非酒精性脂肪性肝病情况分析

doi:10.3969/j.issn.1672-5069.2021.03.016

摘要/Abstract

摘要： 目的回顾颅内出血(ICH)患者合并非酒精性脂肪性肝病(NAFLD)情况并分析其危险因素。方法 2010年1月～2020年6月我院收治的ICH患者146例,使用超声检查诊断脂肪性肝病,采用单因素和多因素Logistic回归分析,明确合并NAFLD的危险因素。结果在本组146例ICH患者中,经超声检查发现NAFLD者52例(35.6%);合并NAFLD组2型糖尿病(T2DM)发生率为32.7%,显著高于非NAFLD组的12.8%(P<0.05),NAFLD组BMI为(25.4±2.4)kg/m²,显著高于非NAFLD组【(23.1±2.7)kg/m²,P<0.05】,NAFLD组血清高密度脂蛋白(HDL)为(1.4±0.5)mmol/L,甘油三酯(TG)为(4.2±1.6)mmol/L,与非NAFLD组【分别为(1.8±0.5)mmol/L和(2.2±1.1)mmol/L】比,差异具有统计学意义(P<0.05),NAFLD组血肿量＞30ml的比率为75.0%,显著高于未合并NAFLD组的39.4%(P<0.05),NAFLD组格拉斯哥昏迷(GCS)评分≤10分的比率为67.3%,显著高于非NAFLD组的37.2%(P<0.05),而两组合并高血压、吸烟、心血管疾病、血管畸形、血清FPG、ALT、AST和感染的比率无统计学差异(P>0.05);多因素Logistic回归分析结果提示合并T2DM、血肿量大和GCS评分低是ICH患者伴有NAFLD的独立危险因素,而血清HDL则是ICH患者不伴有NAFLD的保护性因素(P<0.05)。结论 NAFLD人群可能更容易发生ICH,可能与合并存在的高脂血症、糖尿病和血管病变有关。因此,应该加强对NAFLD人群的筛查和监测,以防止心脑血管疾病的发生,提高生存质量。

关键词: 非酒精性脂肪性肝病, 颅内出血, 格拉斯哥昏迷评分, 血脂

Abstract: Objective The aim of this study was to investigate the prevalence of nonalcoholic fatty liver diseases (NAFLD) in patients with intracerebral hemorrhage (ICH).Methods A total of 146 patients with ICH were treated in our hospital between January 2010 and June 2020, and all underwent sonography for the diagnosis of NAFLD. The univariate and multivariate Logistic regression analysis was applied to confirm the factors for NAFLD coexistence.Results Out of our series, 52 patients (35.6%) were found with underlying NAFLD; the percentage of type two diabetes mellitus (T2DM) in patients with NAFLD was 32.7%, significantly higher than 12.8%(P<0.05) in patients without NAFLD, the body mass index in patients with NAFLD was (25.4±2.4)kg/m², significantly higher than [(23.1±2.7)kg/m², P<0.05] in patients without NAFLD, the blood high-density lipoprotein (HDL) level in patients with NAFLD was (1.4±0.5) mmol/L, significantly lower than (1.8±0.5) mmol/L in patients without NAFLD, the blood triglyceride level was (4.2±1.6)mmol/L, significantly higher than [(2.2±1.1)mmol/L, P<0.05] in patients without NAFLD, the percentage of large intracerebral bleeding volume in patients with NAFLD was 75.0%, significantly higher than 39.4%(P<0.05) in patients without NAFLD, and the percentage of lowGlasgow coma score (GCS) in patients with NAFLD was 67.3%, significantly higher than 37.2%(P<0.05) in patients without NAFLD, while there were not significant differences as respect to the percentages of high blood pressure, smoking, cardiovascular diseases, vascular malformation, increased fasting plasma glucose, serum alanine aminotransferase and aspartate aminotransferase, and infection between the two groups(P>0.05); multivariate Logistic analysis showed that coincidence of T2DM, large intracerebral bleeding and lower GCS were the independent risk factors for underlying NAFLD in this circumstance, and normal blood HDL level was the protective factor for patients without NAFLD(P<0.05). Conclusions The presence of T2DM, intracerebral hematoma volume greater than 30 ml and GCS score less than 10 in patients with ICH might hints the presence of NAFLD, which remind the clinicians dealing appropriately with them in clinical practice.

Key words: Nonalcoholic fatty liver diseases, Intracerebral hemorrhage, Glasgow coma score, Hyperlipoproteinemia

晋颖, 周卫真, 冯世兵, 汪湃. 颅内出血患者合并非酒精性脂肪性肝病情况分析[J]. 实用肝脏病杂志, 2021, 24(3): 367-370.

Jin Ying, Zhou Weizhen, Feng Shibing, et al. Prevalence of nonalcoholic fatty liver diseases in patients with intracerebral hemorrhage[J]. Journal of Practical Hepatology, 2021, 24(3): 367-370.

参考文献

[1] Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/ American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Circulation, 2007, 116(16):e391-e413.
[2]Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet, 2016, 387(10038): 2605-2613.
[3] Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol, 2012, 11(4): 307-314.
[4] Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery, 2006, 59(4): 767-774.
[5] Andaluz N, Zuccarello M. Recent trends in the treatment of spontaneous intracerebral hemorrhage: analysis of a nationwide inpatient database. J Neurosurg, 2009, 110(3): 403-410.
[6] Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2015, 46(7): 2032-2060.
[7] Elkhatib THM, Shehta N, Bessar AA. Hematoma expansion predictors: laboratory and radiological risk factors in patients with acute intracerebral hemorrhage: a prospective observational study. J Stroke Cerebrovasc Dis, 2019, 28(8): 2177-2186.
[8] Rowe AS, Rinehart DR, Lezatte S, et al. Intracerebral hemorrhage after external ventricular drain placement: an evaluation of risk factors for post-procedural hemorrhagic complications. BMC Neurol, 2018, 18(1): 22.
[9] Charidimou A, Boulouis G, Roongpiboonsopit D, et al. Cortical superficial siderosis and recurrent intracerebral hemorrhage risk in cerebral amyloid angiopathy: large prospective cohort and preliminary meta-analysis. Int J Stroke, 2019, 14(7): 723-733.
[10] Reitz M, von Spreckelsen N, Vettorazzi E, et al. Angioarchitectural risk factors for hemorrhage and clinical long-term outcome in pediatric patients with cerebral arteriovenous malformations. World Neurosurg, 2016, 89:540-551.
[11] Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc, 2015, 90(9):1233-1246.
[12] Liu Y, Dai M, Bi Y, et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China. J Epidemiol, 2013, 23(2):115-121.
[13] Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology, 2017, 66(5):1486-1501.
[14] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国颅内出血诊治指南(2019). 中华神经科杂志, 2019, 52(12):994-1005.
[15] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[16] Wijdicks EF, Bamlet WR, Maramattom BV, et al. Validation of a new coma scale: The four score. Ann Neurol, 2005, 58(4):585-593.
[17] Fernández-Friera L, Fuster V, López-Melgar B, et al. Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol, 2017, 70(24):2979-2991.
[18] Li YH, Chen JW, Lin TH, et al. A performance guide for major risk factors control in patients with atherosclerotic cardiovascular disease in Taiwan. J Formos Med Assoc, 2020, 119(3):674-684.
[19] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol, 2019, 71(4):793-801.
[20] Oakkar EE, Stevens J, Truesdale KP, et al. BMI and all-cause mortality among Chinese and Caucasians: the People's Republic of China and the atherosclerosis risk in communities studies. Asia Pac J Clin Nutr, 2015, 24(3):472-479.
[21] Hirsch JA, Moore KA, Barrientos-Gutierrez T, et al. Built environment change and change in BMI and waist circumference: multi-ethnic study of atherosclerosis. Obesity (Silver Spring), 2014, 22(11):2450-2457.
[22] Karlson BW, Palmer MK, Nicholls SJ, et al. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: results from the VOYAGER meta-analysis. Eur J Prev Cardiol, 2016, 23(7):744-747.
[23] Holewijn S, den Heijer M, Swinkels DW, et al. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Intern Med, 2010, 268(6):567-577.
[24] Øie LR, Madsbu MA, Solheim O, et al. Functional outcome and survival following spontaneous intracerebral hemorrhage: a retrospective population-based study. Brain Behav, 2018, 8(10):e01113.
[25] Hegde A, Menon G, Kumar V. Surgery for spontaneous intracerebral hemorrhage - a comparative study with medical management in moderate to large sized hematomas. Clin Neurol Neurosurg, 2019, 184:105415.